Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

1243P - Pathologic response as early endpoint for survival following neoadjuvant therapy (NEO-AT) in resectable non-small cell lung cancer (rNSCLC): Systematic literature review and meta-analysis


17 Sep 2020


E-Poster Display


Nathalie Waser


Annals of Oncology (2020) 31 (suppl_4): S744-S753. 10.1016/annonc/annonc263


N.A. Waser1, A. Adam1, B. Schweikert2, L. Vo3, M. McKenna4, M. Breckenridge3, J.R. Penrod3, S. Goring5

Author affiliations

  • 1 Epidemiology, ICON plc., V6B 1P1 - Vancouver/CA
  • 2 Epidemiology, ICON plc., Munich/DE
  • 3 Worldwide Health Economics & Outcomes Research, Bristol-Myers Squibb, Princeton/US
  • 4 Worldwide Health Economics & Outcomes Research, Health Outcomes Solutions Ltd, London/GB
  • 5 Epidemiology, ICON plc., Vancouver/CA


Abstract 1243P


In rNSCLC, pathological response after NEO-AT has been shown to be associated with long-term outcomes such as event-free survival (EFS) and overall survival (OS). Our objective was to systematically identify and meta-analyze the magnitude of the association from the available literature.


MEDLINE, EMBASE and CENTRAL were searched from database inception to March 2019. Eligible studies included randomized-controlled trials (RCTs), non-randomized trials, and cohorts of patients with rNSCLC treated with NEO-AT reporting OS or EFS by pathological complete response (pCR) status or major pathological response (MPR) status. Study design, baseline characteristics, treatment, and endpoints were extracted and validated. Kaplan-Meier curves were digitized and individual-patient data reconstructed to calculate hazard ratios (HR). HR for OS and HR for EFS by pathologic response status (i.e. pCR vs no-pCR; MPR vs no-MPR) were meta-analyzed using a random-effects model. Subgroup analyses according to endpoint definitions, population, treatment type, and study design were performed.


Among 7,200 records screened, 33 studies were included. Studies were RCTs (n=2), single-arm trials (n=3) or cohorts (n=28), with sample sizes from 26 to 1,750 patients. In all studies, NEO-AT consisted of platinum-based chemotherapy regimens ± radiotherapy. For OS by pCR status, the HRs ranged from 0.13 to 0.78, and the meta-analyzed HR across 21 studies (6,672 patients) was 0.49 (95% CI 0.43-0.56). For EFS by pCR status, the HRs ranged from 0.26 to 0.76, and the meta-analysed HR across 12 studies (2,297 patients) was 0.50 (95% CI 0.40-0.62). The magnitude of the HRs by MPR status were similar to the results by pCR status. Findings were consistent across subgroup analyses.


A strong association between pathological response and survival has been consistently shown in patient-level analyses across studies in the NEO-AT rNSCLC setting. Further research is needed to evaluate how treatment effects on the depth of pathological response relate to estimated treatment effects on survival-based endpoints.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Bristol-Myers Squibb.


Bristol-Myers Squibb.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.